Library — CHDR

Search

Filter

Assessment of dermal absorption of aluminium from a representative antiperspirant formulation using a (Al)Al microtracer approach: a follow-up study in humans.

de Ligt R, Westerhout J, Grossouw D, Buters TP, Rissmann R, Burggraaf J, Windhorst AD, Tozer S, Pappa G, Wall B, Bury D, Mason DR, Vaes WHJ

Toxicology research, 2022 Jun; 11(3):511-519

View publication
Acute response to cholinergic challenge predicts long-term response to galantamine treatment in patients with Alzheimer's disease.

Baakman AC, Gavan C, van Doeselaar L, de Kam M, Broekhuizen K, Bajenaru O, Camps L, Swart EL, Kalisvaart K, Schoonenboom N, Lemstra E, Scheltens P, Cohen A, van Gerven J, Groeneveld GJ

British journal of clinical pharmacology, 2022 Jun; 88(6):2814-2829

View publication
Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo-controlled, double-blind phase I/Ib studies in healthy subjects and patients.

Vissers MFJM, Heuberger JAAC, Groeneveld GJ, Oude Nijhuis J, De Deyn PP, Hadi S, Harris J, Tsai RM, Cruz-Herranz A, Huang F, Tong V, Erickson R, Zhu Y, Scearce-Levie K, Hsiao-Nakamoto J, Tang X, Chang M, Fox BM, Pomponio RJ, Alonso-Alonso M, Zilberstein M, Atassi N, Troyer MD, Ho C

Clinical and translational science, 2022 Jun

View publication
Clinical validation of digital biomarkers for paediatric patients with asthma and cystic fibrosis: potential for clinical trials and clinical care.

Kruizinga MD, Essers E, Stuurman FE, Yavuz Y, de Kam ML, Zhuparris A, Janssens HM, Groothuis I, Sprij AJ, Nuijsink M, Cohen AF, Driessen GJA

The European respiratory journal, 2022 Jun

View publication
Pharmacological profile of ALKS 7119, an investigational compound evaluated for the treatment of neuropsychiatric disorders, in healthy volunteers.

Dijkstra FM, Zuiker RGJA, Siebenga PS, Leigh-Pemberton RA, Sun L, Manthis JD, de Kam ML, Lin R, von Moltke LL, Rezendes D, van Gerven JMA

British journal of clinical pharmacology, 2022 Jun; 88(6):2909-2925

View publication
Modeling buprenorphine reduction of fentanyl-induced respiratory depression.

Olofsen E, Algera MH, Moss L, Dobbins RL, Groeneveld GJ, van Velzen M, Niesters M, Dahan A, Laffont CM

JCI insight, 2022 May

View publication
The effects of intranasal esketamine on on-road driving performance in patients with major depressive disorder or persistent depressive disorder.

Dijkstra FM, van de Loo AJ, Abdulahad S, Bosma ER, Hartog M, Huls H, Kuijper DC, de Vries E, Solanki B, Singh J, Aluisio L, Zannikos P, Stuurman FE, Jacobs GE, Verster JC

Journal of psychopharmacology (Oxford, England), 2022 May; 36(5):614-625

View publication
A Randomized First-in-Human Study With UB-312, a UBITh® α-Synuclein Peptide Vaccine

Hui Jing Yu, Eva Thijssen, Emilie van Brummelen, Johan L. van der Plas, Igor Radanovic, Matthijs Moerland, Eric Hsieh, Geert Jan Groeneveld, Jean-Cosme Dodart

2022 Apr

View publication
Clinical Pharmacology of Radiotheranostics in Oncology.

Te Beek ET, Burggraaf J, Teunissen JJM, Vriens D

Clinical pharmacology and therapeutics, 2022 Apr

View publication

«
1
2
...
9
10
11
12
13
14
15
...
98
99
»